Finance
|
Disappointing Results For AVI's Eteplirsen
Posted on April 02, 2012 at 13:05 PM EDT
AVI Biopharma Inc.'s (Nasdaq: AVII) muscular dystrophy treatment eteplirsen increased levels of the protein dystrophin but failed to improve walking ability in a midstage clinical trial sending the stock price tumbling 45 cents to $1.09.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. Press Release Service provided by PRConnect. Stock quotes supplied by Telekurs USA Postage Rates Bots go here |
| ||||||
